𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C

✍ Scribed by N. Fujita; R. Sugimoto; N. Ma; H. Tanaka; M. Iwasa; Y. Kobayashi; S. Kawanishi; S. Watanabe; M. Kaito; Y. Takei

Book ID
108886127
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
420 KB
Volume
15
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis B and D genomes in hepatitis B
Hepatitis B and D genomes in hepatitis B surface antigen negative patients with chronic hepatitis C
✍ Sara González; Sonia Navas; Antonio Madejón; Javier Bartolomé; Inmaculada Castil 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 607 KB

## Abstract Hepatitis B and hepatitis D viral genomes were tested by nested polymerase chain reaction in the serum and liver of 69 hepatitis B surface antigen (HBsAg) negative, anti‐hepatitis C virus (HCV) positive patients (47 with HCV RNA and 22 without HCV RNA). Serum hepatitis B virus (HBV) DNA

Hepatitis C viral quasispecies and liver
Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection
✍ J Hayashi; Y Kishihara; K Yamaji; N Furusyo; T Yamamoto; Y Pae; Y Etoh; H Ikemat 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

To clarify the virological differences in patients with chronic hepatitis C virus (HCV) infection with and without liver damage, we assessed HCV markers in 306 patients from a rural area of Japan. Genotypes of HCV RNA were determined by polymerase chain reaction, and levels of RNA were determined by

Efficacy of lamivudine in patients with
Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB
✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60